Calcium Phosphate

Mechanism-of-action class: Electrolyte Activity.

• USES For the temporary relief of minor migraine headache pain, headache pain with nausea, headache due to simple nervous tensionICD-10: G43.909, R11.2, R51.9

DIRECTIONS At first sign of symptoms: Adults: 1 tablet every 1/2 to 1 hour until symptoms lessen, then continue with standard dosage. Standard dosage: Adults: Take 1-2 tablets every 4 to 6 hours. Do not exceed 12 tablets in 24 hours. For children under 18, consult your health professional. Allow tablets to dissolve completely in the mouth, do not swallow.

If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. If symptoms persist or worsen, a health professional should be consulted. Ask a doctor before use if you have never had migraines diagnosed by a health professional, you have a headache that is different from your usual migraines, you have the worst headache of your life, you have fever and stiff neck, you have a migraine so severe as to require bed rest. Do not use if known sensitivity to BHI Migraine or any of its ingredients exists.

1. 1Fatigue1708.1%
2. 2Nausea1517.2%
3. 3Diarrhoea1386.6%
4. 4Dizziness1356.4%
5. 5Pain1356.4%
6. 6Headache1316.2%
7. 7Arthralgia1135.4%
8. 8Drug Ineffective1075.1%
9. 9Dyspnoea1014.8%
10. 10Pain In Extremity964.6%
11. 11Asthenia924.4%
12. 12Pruritus864.1%
13. 13Vomiting833.9%
14. 14Insomnia803.8%
15. 15Rash753.6%

Recent PubMed references pinned to Calcium Phosphate as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• Bone Healing Response of Two Different Silicate-Containing Calcium Phosphate Synthetic Bone Grafts in a Rabbit Femoral Critical-Sized Defect Model.
  Journal of biomedical materials research. Part B, Applied biomaterials · 2026 · Gibson IR, Conway JC, Lopes VR, et al.
  PMID 42231723DOI 10.1002/jbm.b.70103
• Dark Field Colored Imaging of Rat Bone Shows the Variation of Nanocrystal Orientation Within and Between Mineral Platelets.
  Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada · 2026 · Bibko A, Schwarcz H, Kovacs Kis V, et al.
  PMID 42229766DOI 10.1093/mam/ozag029
• Bone biochar as a bifunctional catalyst for sustainable co-removal of nitrate and phosphate in constructed wetlands.
  Water research · 2026 · Liu T, Qin H, Li S, et al.
  PMID 42214875DOI 10.1016/j.watres.2026.126188
• Evaluating the Effects of Poly(ε-Caprolactone)-Nanohydroxyapatite Composition on 3D-Printed Scaffold Structural Properties.
  Journal of biomedical materials research. Part A · 2026 · Kennedy MM, Kolliopoulos VK, Loukelis K, et al.
  PMID 42206654DOI 10.1002/jbm.a.70094
• Phosphate-Mediated Regulation of Intracellular Calcium Dynamics.
  Cells · 2026 · Shahzad H, Razzaque MS
  PMID 42193909DOI 10.3390/cells15100901
• Phosphate removal, recovery, and upcycling by wollastonite and calcium phosphate mineral-hydrogel composites.
  Water research · 2026 · Tan AX, Jung M, Jun YS, et al.
  PMID 42177894DOI 10.1016/j.watres.2026.126006
• Mechanism-guided biomimetic calcium phosphate mineralization on agro-derived nanocellulose, chitosan, and pectin: Interfacial design rules for translation.
  Carbohydrate polymers · 2026 · Vega-Baudrit JR, Lopretti M
  PMID 42173568DOI 10.1016/j.carbpol.2026.125306
• Highly porous PLA nanofibers containing borate bioactive glass: hydroxyapatite formation, cytocompatibility, and osteogenic mineralization.
  Biomedical materials (Bristol, England) · 2026 · Ribeiro Dos Santos Borges V, Freire Sant'Anna de Oliveira E, Borges ALS, et al.
  PMID 42173139DOI 10.1088/1748-605X/ae722c

The 10 most recently updated of 625 ClinicalTrials.gov registrations naming Calcium Phosphate as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
  Recruiting · Phase 2 · Interventional · 461 enrolled · National Cancer Institute (NCI)
  NCT04546399updated 2026-06-12
• Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies
  Recruiting · Phase 1 · Phase 2 · Interventional · 44 enrolled · M.D. Anderson Cancer Center
  NCT06383572updated 2026-06-12
• Dexamethasone in Controlling Dyspnea in Patients With Cancer
  Active not recruiting · Phase 2 · Interventional · 135 enrolled · M.D. Anderson Cancer Center
  NCT03367156updated 2026-06-11
• Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
  Active not recruiting · Phase 1 · Interventional · 24 enrolled · National Cancer Institute (NCI)
  NCT04847453updated 2026-06-11
• Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
  Active not recruiting · Phase 3 · Interventional · 525 enrolled · National Cancer Institute (NCI)
  NCT00644228updated 2026-06-11
• Assessment of the Impact of Neobone® (Biphasic Calcium Phosphate) on Bone Volume in Alveolar Ridge Preservation After Tooth Extraction
  Recruiting · Early phase 1 · Interventional · 30 enrolled · Egas Moniz - Cooperativa de Ensino Superior, CRL
  NCT07638358updated 2026-06-11
• Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
  Recruiting · Phase 2 · Interventional · 153 enrolled · National Cancer Institute (NCI)
  NCT06317662updated 2026-06-11
• Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma
  Completed · Phase 1 · Interventional · 83 enrolled · Thomas Martin, MD
  NCT02332850updated 2026-06-11
• Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
  Recruiting · Phase 3 · Interventional · 510 enrolled · SWOG Cancer Research Network
  NCT05561387updated 2026-06-10
• Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment
  Not yet recruiting · Phase 2 · Interventional · 90 enrolled · SWOG Cancer Research Network
  NCT07636564updated 2026-06-09

Frequently asked questions

How does Calcium Phosphate work?

Mechanism-of-action class: Electrolyte Activity.

What is Calcium Phosphate used for?

According to FDA labeling, Calcium Phosphate carries indications including: USES For the temporary relief of minor migraine headache pain, headache pain with nausea, headache due to simple nervous tension. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.

What class of drug is Calcium Phosphate?

Calcium Phosphate is classified as Calcium, Electrolyte Activity, Bone Resorption Alteration, Increased Renal PO4-- Excretion.

What are the brand names for Calcium Phosphate?

Calcium Phosphate is marketed under brand names including Medi-Lyte.